[go: up one dir, main page]

MX368838B - Administracion sublingual de riluzol. - Google Patents

Administracion sublingual de riluzol.

Info

Publication number
MX368838B
MX368838B MX2017006446A MX2017006446A MX368838B MX 368838 B MX368838 B MX 368838B MX 2017006446 A MX2017006446 A MX 2017006446A MX 2017006446 A MX2017006446 A MX 2017006446A MX 368838 B MX368838 B MX 368838B
Authority
MX
Mexico
Prior art keywords
riluzole
sublingual formulation
sublingual
disclosed
formulation
Prior art date
Application number
MX2017006446A
Other languages
English (en)
Other versions
MX2017006446A (es
Inventor
Yu Danny
Coric Vladimir
Samuel Vladyka Ronald
Saleh Amgad
Berman Robert
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of MX2017006446A publication Critical patent/MX2017006446A/es
Publication of MX368838B publication Critical patent/MX368838B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se da a conocer la administración sublingual de riluzol. En particular, se proporciona un método para tratar un trastorno o síntoma neuropsiquiátrico al administrar una formulación sublingual de riluzol. Además, se describe un método para aliviar o reducir el dolor oral usando la formulación sublingual de riluzol.
MX2017006446A 2014-11-21 2015-11-17 Administracion sublingual de riluzol. MX368838B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083094P 2014-11-21 2014-11-21
PCT/US2015/061114 WO2016081472A1 (en) 2014-11-21 2015-11-17 Sublingual formulation of riluzole

Publications (2)

Publication Number Publication Date
MX2017006446A MX2017006446A (es) 2018-02-12
MX368838B true MX368838B (es) 2019-10-18

Family

ID=55085882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006446A MX368838B (es) 2014-11-21 2015-11-17 Administracion sublingual de riluzol.

Country Status (24)

Country Link
US (2) US11660267B2 (es)
EP (3) EP3220891B1 (es)
JP (3) JP6753860B2 (es)
KR (2) KR20230135183A (es)
CN (1) CN107249567B (es)
AU (2) AU2015350148B2 (es)
BR (1) BR112017010423B1 (es)
CA (1) CA2967662A1 (es)
CY (1) CY1122469T1 (es)
DK (1) DK3220891T3 (es)
EA (1) EA038518B1 (es)
ES (2) ES2751300T3 (es)
HR (1) HRP20191892T8 (es)
HU (1) HUE046869T2 (es)
IL (2) IL278188B1 (es)
LT (1) LT3220891T (es)
MX (1) MX368838B (es)
PH (1) PH12017500934B1 (es)
PL (1) PL3220891T3 (es)
PT (1) PT3220891T (es)
RS (1) RS59490B1 (es)
SG (1) SG11201703896QA (es)
SI (1) SI3220891T1 (es)
WO (1) WO2016081472A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
MX2020008680A (es) * 2018-02-21 2020-09-25 Ai Therapeutics Inc Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2020012377A (es) * 2018-05-27 2021-04-12 Biohaven Therapeutics Ltd Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
KR20210045423A (ko) * 2018-08-16 2021-04-26 바이오하벤 테라퓨틱스 리미티드 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도
US20210113557A1 (en) * 2019-10-22 2021-04-22 Arvinas Operations, Inc. Methods of treating prostate cancer
JP2023524599A (ja) 2020-05-09 2023-06-12 アルビナス・オペレーションズ・インコーポレイテッド 二官能性化合物を製造する方法、二官能性化合物の超高純度形態、及びそれらを含む剤形
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN113876735B (zh) * 2021-10-20 2023-05-12 陇南市第一人民医院 一种利鲁唑微球制剂及其制备方法
KR102625977B1 (ko) 2021-11-24 2024-01-17 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
EP0946111B1 (de) * 1996-12-20 2004-02-25 Nutrinova Nutrition Specialties & Food Ingredients GmbH Verfahren zur verstärkung der süsskraft und zur geschmacksverbesserung einer mischung hochintensiver süssstoffe
DE69840495D1 (de) 1997-02-20 2009-03-12 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
JP4947833B2 (ja) 1997-07-25 2012-06-06 アルペックス・ファルマ・ソシエテ・アノニム 速崩壊性口内溶解錠の製造に適した顆粒の製造方法
EE05190B1 (et) 1998-11-20 2009-08-17 Rtp Pharma Inc. Dispergeeruvad fosfolipiididega stabiliseeritud mikroosakesed
AU2173400A (en) * 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP2001328947A (ja) * 2000-05-19 2001-11-27 Ritsuko Senba 脳由来神経栄養因子発現促進剤
US6432992B1 (en) * 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US6908626B2 (en) 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
WO2003068604A1 (en) 2002-02-13 2003-08-21 Weibel Michael K Drug dose-form and method of manufacture
WO2004105756A2 (en) * 2003-05-29 2004-12-09 Novartis Ag Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP1980240A1 (en) 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PREPARING RAPID DISAGGREGATION FORMULATION FOR ORAL ADMINISTRATION AND APPARATUS FOR PREPARING AND PACKAGING THEREFOR
US20110183942A1 (en) * 2008-07-15 2011-07-28 University Of Medicine And Dentistry Of New Jersey Methods and Compositions for Treating Alzheimer's Disease
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
WO2010096869A1 (en) * 2009-02-26 2010-09-02 Steven Michael Weiss An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
AU2012222351B2 (en) * 2011-03-01 2017-05-18 Pharnext Baclofen and Acamprosate based therapy of neurogical disorders
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
WO2013010015A2 (en) * 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
CA2864008C (en) * 2012-03-01 2020-04-21 Pharnext New compositions for treating amyotrophic lateral sclerosis
SG11201703897SA (en) 2014-11-21 2017-06-29 Biohaven Pharm Holding Co Ltd Sublingual administration of riluzole
JP6700293B2 (ja) * 2015-03-03 2020-05-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用

Also Published As

Publication number Publication date
EP3616686B1 (en) 2021-05-19
PH12017500934B1 (en) 2024-06-28
KR20170137032A (ko) 2017-12-12
HUE046869T2 (hu) 2020-04-28
KR20230135183A (ko) 2023-09-22
US20210038499A1 (en) 2021-02-11
EP3220891A1 (en) 2017-09-27
EA038518B1 (ru) 2021-09-09
KR102580378B1 (ko) 2023-09-19
JP2021001173A (ja) 2021-01-07
JP2017535613A (ja) 2017-11-30
DK3220891T3 (da) 2019-11-04
WO2016081472A1 (en) 2016-05-26
IL252285A0 (en) 2017-07-31
PL3220891T3 (pl) 2020-08-24
BR112017010423A2 (pt) 2017-12-26
SI3220891T1 (sl) 2020-02-28
CY1122469T1 (el) 2021-01-27
EP4039247A2 (en) 2022-08-10
US11660267B2 (en) 2023-05-30
US12121609B2 (en) 2024-10-22
SG11201703896QA (en) 2017-06-29
EP3616686A1 (en) 2020-03-04
US20180153794A1 (en) 2018-06-07
IL278188A (en) 2020-11-30
HRP20191892T8 (hr) 2020-09-18
CN107249567B (zh) 2021-08-03
AU2015350148B2 (en) 2020-11-26
CA2967662A1 (en) 2016-05-26
EP3220891B1 (en) 2019-07-24
AU2015350148A1 (en) 2017-06-15
LT3220891T (lt) 2019-11-11
EA201790958A1 (ru) 2018-01-31
EP4039247A3 (en) 2022-11-16
RS59490B1 (sr) 2019-12-31
JP2023065398A (ja) 2023-05-12
BR112017010423B1 (pt) 2023-09-26
PH12017500934A1 (en) 2017-11-20
JP6753860B2 (ja) 2020-09-09
MX2017006446A (es) 2018-02-12
IL252285B (en) 2020-10-29
HRP20191892T1 (hr) 2020-01-10
ES2882783T3 (es) 2021-12-02
ES2751300T3 (es) 2020-03-31
AU2021201034B2 (en) 2023-07-06
IL278188B1 (en) 2024-11-01
PT3220891T (pt) 2019-10-31
AU2021201034A1 (en) 2021-03-11
EP3616686B8 (en) 2021-06-23
CN107249567A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
PH12017500933A1 (en) Sublingual administration of riluzole
PH12017500934A1 (en) Sublingual formulation of riluzole
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
TW201713333A (en) Methods of treating a neurodegenerative disease
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
NZ722600A (en) Methods of treating mild brain injury
SG10201804034QA (en) Methods for treating hypotension
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
MX2018011379A (es) Tratamiento del prurito uremico.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
MX2016011706A (es) Formulaciones de progesterona.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MA40574A (fr) Traitement de maladies fibrotiques
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA104614U (uk) Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих

Legal Events

Date Code Title Description
FG Grant or registration